Novo Nordisk A/S NVO.N, NVO is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025
The Bagsvaerd Denmark-based company is expected to report a 19.5% increase in revenue to DKK78.08 billion from DKK65.35 billion a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Novo Nordisk A/S is for earnings of DKK6.11 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Novo Nordisk A/S is $100.00, above its last closing price of $69.23.
Previous quarterly performance (using preferred earnings measure in Danish crowns).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 5.87 | 5.86 | 6.34 | Beat | 8.1 |
Sep. 30 2024 | 6.04 | 6.02 | 6.12 | Beat | 1.6 |
Jun. 30 2024 | 4.64 | 4.77 | 4.49 | Missed | -5.9 |
Mar. 31 2024 | 5.10 | 5.13 | 5.68 | Beat | 10.8 |
Dec. 31 2023 | 4.47 | 4.47 | 4.91 | Beat | 9.9 |
Sep. 30 2023 | 4.94 | 5.01 | 5.00 | Missed | -0.3 |
Jun. 30 2023 | 4.45 | 4.35 | 4.32 | Missed | -0.7 |
Mar. 31 2023 | 4.29 | 4.33 | 4.39 | Beat | 1.3 |
This summary was machine generated May 5 at 05:34 GMT. All figures in Danish crowns unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。